证券代码：688085 证券简称：三友医疗 公告编号：2025-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海三友医疗器械股份有限公司（以下简称"公司"）于近日完成注册资本 变更及《公司章程》备案相关的工商登记手续，并取得了上海市市场监督管理局 换发的《营业执照》，具体情况如下： 一、关于变更公司注册资本、修订《公司章程》的情况 公司于 2025 年 2 月 27 日召开第三届董事会第二十三次会议审议通过《关于 变更公司注册资本并办理工商变更登记的议案》、《关于修订<公司章程>的议案》， 同意公司注册资本由 248,453,535 元变更为 264,852,529 元，并相应修订了《公司 章程》第六条、第十八条。具体情况详见公司于 2025 年 2 月 28 日披露于上海证 券交易所网站的《关于变更公司注册资本、修订<公司章程>并办理工商变更的 公告》（公告编号：2025-011）。上述事项已经公司 2025 年第一次临时股东大会 审议通过。 类型：股份有限公司（港澳台投资、上市） 上海三友医疗器械股份有限公 ...

证券代码：688085 证券简称：三友医疗 公告编号：2025-026 上海三友医疗器械股份有限公司 2025年第二次临时股东大会决议公告 本次会议由公司董事会召集，董事长 Michael MingYan Liu（刘明岩）先生主 持。本次会议的召集、召开程序等均符合《公司法》、《公司章程》等的相关规定。 （五） 公司董事、监事和董事会秘书的出席情况 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 39 | | --- | --- | | 普通股股东人数 | 39 | | 2、出席会议的股东所持有的表决权数量 | 83,713,246 | | 普通股股东所持有表决权数量 | 83,713,246 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 30.125 | | 例（%） | | | 普通股股东所持 ...

Core Viewpoint - Shanghai Sanyou Medical Devices Co., Ltd. is preparing for its upcoming shareholders' meeting, emphasizing the importance of maintaining order and protecting shareholders' rights during the proceedings [1][2][3]. Meeting Procedures - The meeting will follow a structured agenda as outlined in the notice, allowing shareholders and their representatives to exercise their rights to speak, inquire, and vote [2][3]. - Shareholders must register to speak at least one day prior to the meeting, and questions must be relevant to the agenda [2][3]. - The meeting will include a combination of on-site and online voting, with specific timeframes for each voting method [5][6]. Capital Changes - The company has completed the registration of new shares following a capital increase, raising the total share capital from 264,852,529 shares to 277,885,415 shares, with an increase of 13,032,886 shares [6][7]. - A proposal to amend the company's registered capital and revise the Articles of Association will be presented for shareholder approval [6][7][8]. Articles of Association Revision - The revision of the Articles of Association is necessary due to changes in the total number of shares and registered capital, with the new registered capital set at RMB 277,885.415 million [7][8].

上海三友医疗器械股份有限公司 证券代码：688085 证券简称：三友医疗 上海三友医疗器械股份有限公司 2025 年第二次临时股东大会 会议资料 二 O 二五年四月 | 2025 年第二次临时股东大会会议须知 2 | | --- | | 2025 年第二次临时股东大会会议议程 4 | | 议案一 6 | | 关于变更公司注册资本并办理工商变更登记的议案 6 | | 议案二 7 | | 关于修订《公司章程》的议案 7 | 上海三友医疗器械股份有限公司 上海三友医疗器械股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的 顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 大会规则》以及《上海三友医疗器械股份有限公司章程》《上海三友医疗器械股份有限 公司股东大会议事规则》等相关规定，上海三友医疗器械股份有限公司（以下简称"公 司"）特制定本次股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将 对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严 ...

Core Viewpoint - The report provides a verification of Shanghai Sanyou Medical Instrument Co., Ltd.'s pre-investment of self-raised funds into fundraising projects and payment of issuance expenses, confirming compliance with regulatory requirements [1][3]. Group 1: Verification Report - The verification report is intended solely for the purpose of replacing self-raised funds with raised funds for investment projects and issuance expenses [2]. - The management of Sanyou Medical is responsible for providing accurate and complete information in accordance with regulatory guidelines [2]. - The registered accountants conducted the verification in accordance with Chinese CPA standards, ensuring that the information is free from material misstatement [2]. Group 2: Fundraising Overview - The total amount raised from the issuance is RMB 213,999,988.12, with net proceeds after fees amounting to RMB 203,920,127.60 [4][5]. - The company incurred a financial advisory and underwriting fee of RMB 8,702,599.81, which includes VAT [5]. - The net amount raised was verified by an external accounting firm, providing a verification report [4]. Group 3: Investment Project Details - The company plans to use the raised funds primarily for cash consideration in transactions, with 93.85% allocated for this purpose [5]. - As of February 28, 2025, the actual investment amount from self-raised funds into the projects was RMB 57,217,758.05, representing 26.74% of the total planned usage [5][6]. - Specific allocations include RMB 20,084.88 million for cash consideration and RMB 1,315.12 million for intermediary fees and taxes [5]. Group 4: Issuance Expense Payments - The total amount paid from self-raised funds for issuance expenses was RMB 975,324.54 [6]. - Breakdown of issuance expenses includes RMB 821.00 million for financial advisory and underwriting fees, and RMB 101.89 million for audit and verification fees [8].

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）第三 届监事会第十七次会议于 2025 年 3 月 26 日以现场会议方式召开。本次会议的通 知于 2025 年 3 月 21 日通过邮件方式送达全体监事。会议应出席监事 3 人，实际 到会监事 3 人，会议由监事会主席马宇立先生主持，本次监事会会议的召集和召 开程序符合有关法律、行政法规、部门规章、规范性文件和 公司章程》的规定， 会议决议合法、有效。 证券代码：688085 证券简称：三友医疗 公告编号：2025-024 上海三友医疗器械股份有限公司 第三届监事会第十七次会议决议公告 二、监事会会议审议情况 议案内容：详见公司同日刊载于上海证券交易所网站 （www.sse.com.cn）的 公司 关于调整部分募投项目内部投资结构及部分募投项目延期的公告》，公告 编号：2025-021。 表决情况：同意 3 票，弃权 0 票，反对 0 票。 （三）审议通过 关于使用募集资金置换预先投入募投 ...

Meeting Overview - The third meeting of the supervisory board of Shanghai Sanyou Medical Instrument Co., Ltd. was held on March 26, 2025, with all three supervisors present [1][2] - The meeting was legally convened and chaired by Mr. Ma Yuli, ensuring compliance with relevant laws and regulations [1] Resolutions Passed - The board approved the proposal regarding the completion of certain fundraising projects, with unanimous support (3 votes in favor) [2] - The board approved the adjustment of the internal investment structure of certain fundraising projects and the postponement of some projects, also with unanimous support (3 votes in favor) [2] - The board approved the use of raised funds to replace self-raised funds that were previously invested in fundraising projects and to cover issuance costs, again with unanimous support (3 votes in favor) [2]

Core Viewpoint - The company announced adjustments to the internal investment structure of certain fundraising projects and the postponement of the "Medical High-Strength Suture and Related Orthopedic Soft Tissue Repair Reconstruction Medical Device Project" to December 31, 2027, without changing the overall direction, total investment amount, functionality, or implementation entity of the fundraising projects [1][6]. Fundraising Basic Situation - The company was approved to publicly issue 51,333,500 shares at a price of RMB 20.96 per share, raising a total of RMB 1,075,950,160, with net proceeds of RMB 978,057,381.28 after deducting issuance costs [1][2]. Fundraising Investment Projects - The total investment for the fundraising projects is RMB 62,200,000, with a committed investment amount of RMB 60,000,000 [3]. Internal Structure Adjustment and Postponement - The internal structure adjustment of the fundraising project involves reducing certain personnel costs and research expenses while increasing construction costs. The total investment remains at RMB 4,500,000 [4][5]. - The project timeline has been extended from March 2025 to December 2027 due to delays in construction, product registration, and other factors [6][7]. Necessity and Feasibility of Project Implementation - The project is necessary due to the limited suppliers in the domestic orthopedic sports medicine field and the need for customized equipment from overseas, which has caused delays [7]. - The company has established a robust research and development system in the field of sports medicine and has already made significant investments in funding, equipment, and personnel, ensuring the feasibility of the project [7][8]. Review Procedures - The adjustments were approved by the company's board and supervisory committee, and the sponsor institution confirmed that the necessary decision-making procedures were followed, with no need for shareholder meeting approval [8][9].

Core Viewpoint - The company has announced the use of raised funds to replace self-raised funds previously invested in projects and to cover issuance expenses, following the approval of its board and supervisory committee [1][5][6]. Fundraising Overview - The company was authorized to raise up to 214 million yuan through the issuance of shares at a price of 16.42 yuan per share, resulting in a total fundraising amount of approximately 214 million yuan, with a net amount of about 204 million yuan after deducting issuance costs [2][3]. - A special account for the management of the raised funds has been established with Shanghai Pudong Development Bank, ensuring regulatory oversight [2]. Investment and Expenditure Details - As of February 28, 2025, the actual investment amount from self-raised funds in the projects was approximately 57.22 million yuan, with 56.24 million yuan allocated for cash consideration and 975,324.54 yuan for issuance expenses [3][5]. - The total amount to be replaced by the raised funds is 57.22 million yuan, which includes both the cash consideration and issuance expenses [5]. Compliance and Approval Process - The decision to use raised funds for replacing self-raised funds was made in accordance with relevant laws and regulations, ensuring that it does not alter the intended use of the raised funds or harm the interests of shareholders [6][7]. - The supervisory committee and independent financial advisor have both provided positive opinions on the matter, confirming that the necessary procedures were followed and that the action aligns with the company's operational needs [6][7].

东方证券股份有限公司关于 上海三友医疗器械股份有限公司 部分募投项目结项的核查意见 | 单位：万元 | | --- | | 序号 | 项目名称 | 投资总额 | 拟用募集资金投资额 | | --- | --- | --- | --- | | 1 | 骨科植入物扩产项目 | 24,916.37 | 22,716.37 | | 2 | 骨科产品研发中心建设项目 | 10,775.67 | 10,775.67 | | 3 | 营销网络建设项目 | 7,723.38 | 7,723.38 | | 4 | 补充流动资金 | 18,784.58 | 18,784.58 | | | 合计 | 62,200.00 | 60,000.00 | 注：上表中"骨科植入物扩产项目"已结项，经公司 2022 年第二次临时股东大会审议， 公司使用其节余的部分募集资金 4,500.00 万元新增募投项目"医用高强缝合线及相关的骨 科软组织修复重建医疗器械项目"，该项目计划总投资额为 4,500.00 万元。 东方证券股份有限公司（以下简称"保荐机构"）作为上海三友医疗器械股 份有限公司（以下简称"三友医疗"、"公司"）首次公开发行股票并在 ...